GlassScriptPhysician profile
Carlos Torres-Rivera
NPI 1215032446
$2,633.73
in general payments reported to CMS, 2019-2025
17 companies · $82.89 in 2025
The $82.89 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $472 · 2021: $737 · 2022: $574 · 2023: $404 · 2025: $82.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416 · Education: $70.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.43 |
| Education | $70.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $559.94 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $432.59 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $323.75 | 2019-2023 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $291.78 | 2019-2023 | Lokelma |
| Vifor Pharma, INC. | $128.47 | 2020-2023 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $125.49 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $117.38 | 2020-2022 | |
| Travere Therapeutics, INC. | $108.71 | 2022-2025 | Filspari |
| Calliditas Therapeutics US INC. | $103.19 | 2022-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $94.77 | 2019 | |
| Amgen INC. | $92.11 | 2019-2022 | |
| Baxter Healthcare | $87.52 | 2021 | |
| Glaxosmithkline, LLC. | $55.14 | 2021 | |
| Akebia Therapeutics INC | $40.32 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $27.16 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $22.72 | 2022 | |
| Novo Nordisk INC | $22.69 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Torres-Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.